Contezolid

康替唑胺

Report date: 2026/02/13 20:01:31
NMEQIDP

Base Information

Drug NameContezolid
Drug Alias Name康泰唑胺优喜泰MRX-IMRX-1
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Oxazolidinone antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsProtein biosynthesis inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsComplicated Skin and Soft Tissue InfectionsDiabetic FootSoft Tissue Infections +[7] 
Global Approved IndicationsComplicated Skin and Soft Tissue Infections
Approved Indications in ChinaComplicated Skin and Soft Tissue Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMicuRx Pharmaceutical Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Chest Hospital,Capital Medical UniversityShanghai MicuRx Pharmaceutical Co LtdZhejiang Huahai Pharmaceutical Co Ltd
Inactive CompaniesMicuRx Pharmaceutical IncMengke Medical Technology (Shanghai) Co Ltd
Active IndicationsComplicated Skin and Soft Tissue InfectionsDiabetic FootMycobacterium Infections, Nontuberculous +[4] 
Inactive IndicationsSoft Tissue InfectionsSkin Diseases, InfectiousBacterial Infections

Other Information

ATC CodeJ01XX
Related LinksN/A